放疗联合唑来膦酸治疗骨转移癌止痛疗效分析

摘要

Objective:To evaluate the effect of radiotherapy combined with zoledronic acid in patients with tumors of bone metastasis. Method:From May 2008 to May 2011,62 patients with bone metastasis were randomly divided into radiotherapy group(31 patients)and radiotherapy combined with zoledronic acid group(31 patients). Radiotherapy group was only treated by radiotherapy. Radiotherapy combined with zoledronic acid group was treated by zoledronic acid 4 mg,once every four weeks,total 4-6 cycles,and combined with radiotherapy,DT 40-50 Gy/20-25 fx/4-5 w,or DT 30 Gy/10 fx/2 w. Result:For the effect of pain-relief,partial response rate of only radiotherapy group and combination group was 71.0%,93.5%(X2=5.42, P<0.05). There were significant differences between the two groups. And for movement capacity improvement,partial response rate of only radiotherapy group and combination group was 61.3%,83.9%(X2=3.97,P<0.05). There were significant differences between the two groups. Conclusion:Radiotherapy combination with zoledronic acid can improve the patients’ life quality. It is worthy of further clinical trial.%　　目的：观察放疗联合唑来膦酸对骨转移癌的疗效.方法：将2008年5月-2011年5月本院收治的62例骨转移癌患者分放疗联合唑来膦酸组和单纯放疗组.放疗联合唑来膦酸组第1天应用唑来膦酸4 mg静滴，每4周重复，不少于4次，第2天开始行局部放疗，放疗剂量，常规分割DT 40~50 Gy/20~25次/4~5周；大分割DT 30 Gy/10次/2周；单纯放疗组行单纯局部放疗，观察两组止痛疗效及活动能力改善情况.结果：放疗联合唑来膦酸组止痛效果和活动能力改善情况优于单纯放疗组，比较差异有统计学意义(P<0.05).结论：放疗联合唑来膦酸治疗骨转移癌可提高疼痛缓解率及活动能力，不明显增加毒副作用，值得临床进一步研究.